Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P38
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -3.22% |
| Q2 2025 | 54.27% |
| Q1 2025 | 11.49% |
| Q4 2024 | -14.21% |
| Q3 2024 | 102.76% |
| Q2 2024 | -84.14% |
| Q1 2024 | 1488.32% |
| Q4 2023 | 49.48% |
| Q3 2023 | -73.19% |
| Q2 2023 | -22.47% |
| Q1 2023 | -2.66% |
| Q4 2022 | -12.35% |
| Q3 2022 | -17.25% |
| Q2 2022 | -11.21% |
| Q1 2022 | -16.73% |
| Q4 2021 | 9.09% |
| Q3 2021 | -16.06% |
| Q2 2021 | -50.13% |
| Q1 2021 | 99.46% |
| Q4 2020 | 42.44% |
| Q3 2020 | 49.94% |
| Q2 2020 | 24.10% |
| Q1 2020 | 64.02% |
| Q4 2019 | 66.73% |
| Q3 2019 | -53.04% |
| Q2 2019 | 9.16% |
| Q1 2019 | 69.53% |
| Q4 2018 | 91.46% |
| Q3 2018 | -3.22% |
| Q2 2018 | -34.37% |
| Q1 2018 | -15.88% |
| Q4 2017 | 103.33% |
| Q3 2017 | 95.40% |
| Q2 2017 | -48.20% |
| Q1 2017 | 23.30% |
| Q4 2016 | -83.13% |
| Q3 2016 | 83.14% |
| Q2 2016 | 9.09% |
| Q1 2016 | 30.97% |
| Q4 2015 | 41.51% |